Navigation Links
AstraZeneca Responds to FDA Joint Advisory Committees' Recommendation on SYMBICORT(R)
Date:12/11/2008

inhaled short-acting beta2-agonists. Administered twice daily, SYMBICORT is a combination of two proven asthma medications-budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on other asthma-controller medications (e.g., low-to-medium dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled U.S. study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting beta2-adrenergic agonist), one of the active ingredients in SYMBICORT.

SYMBICORT is not indicated for the relief of acute bronchospasm.

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma.

Particular care is needed for patients who are transferred from systemically active corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.

Patients who are receiving SYMBICORT twice daily should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason.

Common adverse events reported in clinical trials, occurring in less than or
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays 2Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays 3Frost & Sullivan: Western European Markets Confirm Undisputed Convenience and Cost Benefit of Custom Procedure Trays 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 2$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 3$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 4$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 5$232 Billion Personalized Medicine Market to Grow 11 Percent Annually, says PricewaterhouseCoopers 6Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 2Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 3Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines 4National Alliance for Hispanic Health Applauds Confirmation of Sonia Sotomayor as the Nations 111th Supreme Court Justice 53920 1The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 1The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 2The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 3The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 4The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 5The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 6The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 7The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 8The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 9The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 10The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 11The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 12The Ensign Group Reports Second Quarter 2009 Earnings of 240 39 per Share 3B Reaffirms 2009 EPS Guidance 53917 13Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 1Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 2Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 3Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 4Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 5Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 6Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 7Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 8Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 9Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 10Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 11Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 12Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 13Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 14Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 15Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 16Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 17Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 18Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 19Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 20Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 21Cogdell Spencer Inc Reports Second Quarter 2009 Financial Results 53914 22
Breaking Medicine News(10 mins):Health News:The Logo Loft Hires Laid-Off Sales Executive Increasing Sales for Company by 15% Despite the Recession 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 2Health News:Union Hospital, Hong Kong, Selects First DataBank's Electronic Drug Information in Medication Safety Initiative 3Health News:Life Science And Medical Device Software Engineering Consulting Firm Full Spectrum Software Announces 12 New Contract Wins In 2009 2Health News:Unanimous Vote Creates Largest RN Union in U.S. History 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5